1. Skeletal muscle loss and associated clinical outcomes in patients with small-cell lung cancer receiving concurrent chemoradiotherapy. Park SE, Hwang IG, Choi JH. BMC Cancer. 2025 Nov 17;25(1):1772.
2. Risk Factors for Progressive Disease After Immune Checkpoint Inhibitor Therapy in Head and Neck Squamous Cell Carcinoma. Jang SY, Lee YG, Chun SH, Park JH, Park KU, Chang H, Lee KW, Kim HR, Shin SH, An HJ, Lee KE, Hwang IG, Ahn MJ, Kim SB, Keam B. Head Neck. 2025 Jun;47(6):1621-1630.
3. Preoperative thrombocytopenia as a predictor of cancer-associated thromboembolism in gastric cancer patients undergoing gastrectomy. Jung M, Park SE, Choi JH, Kim JE, Hwang IG. Front Oncol. 2025 Jul 16;15:1585201.
4. Association between Antipsychotic Drug and Survival in Patients with Lung Cancer Treated with Chemoradiotherapy: A Nationwide Korean Cohort Study. Kim DY, Hwang IG, Kim SM, Kang DR, Go TH, Hong SH, Park SY, Lee H, Choi JH. Cancer Res Treat. 2025 Oct;57(4):1030-1039.
5. Identifying predictive markers of head and neck squamous cell carcinoma in an umbrella trial (KCSG HN 15-16 TRIUMPH trial). Hwang S, Hong MH, Shin SH, Yun T, Lee KW, Kim JH, Ahn MJ, Keam B, Lee HW, Kim MK, Yun HJ, Kim Y, Kim HJ, Cho SH, An HJ, Oh SY, Park SG, Koh YW, Ahn HK, Kwon JH, Lee YG, Park KU, Hwang IG, Kim SB, Kim S, Kim HR; KCSG TRIUMPH investigators. ESMO Open. 2025 Oct;10(10):105772.
6. Platform study of circulating tumor DNA directed adjuvant chemotherapy in colon cancer (CLAUDIA colon cancer, KCSG CO22-12). Cha Y, Cho SH, Park EY, Lee DE, Park T, Choi MK, Hwang IG, Beom SH, Kang BW, Kim JS, Kim SY, Kim ST, Kang SY, Kim JW, Han SW; Korean Cancer Study Group. BMC Cancer. 2025 Aug 25;25(1):1373.
7. Use of antipsychotic drugs during radiotherapy in adult cancer patients in Korea: a nationwide retrospective cohort study based on the national health insurance service database. Hwang IG, Park SE, Kim SM, Kang DR, Go TH, Hong SH, Ha YC, Park SY, Lee H, Choi JH. Radiat Oncol. 2024 Nov 29;19(1):171.
8. Treatment Patterns and Prognosis of Palliative Chemotherapy Combined With Targeting Agents in Patients With Unresectable Metastatic Colorectal Cancer: CHOICE, A Multicenter Longitudinal Observational Study. Kim JH, Cha Y, Shin SJ, Park YS, Kang JH, Kim C, Lim SH, Kang MJ, Kim JG, Hwang IG, Choi JK, Shin SH, Kang SY, Lee SC, Lim ST, Kim JS, Jeung HC, Kang MH, Choi IS, Ryu HW, Lee KH, Lee MH, Lee JY, Park JH, Jeon SY, Lee N, Park CY, Kim YH. Anticancer Res. 2024 Jan;44(1):347-359.
9. Nationwide precision oncology pilot study: KOrean Precision Medicine Networking Group Study of MOlecular profiling-guided therapy based on genomic alterations in advanced solid tumors (KOSMOS) KCSG AL-20-05. Kim TY, Kim SY, Kim JH, Jung HA, Choi YJ, Hwang IG, Cha Y, Lee GW, Lee YG, Kim TM, Lee SH, Lee S, Yun H, Choi YL, Yoon S, Han SW, Kim TY, Kim TW, Zang DY, Kang JH. ESMO Open. 2024 Oct;9(10):103709.
10. Efficacy of transdermal buprenorphine patch for managing withdrawal symptoms in patients with cancer physically dependent on prescription opioids. Kang JH, Lee KH, Huh SJ, Shin SH, Kim IH, Hwang IG, Koo DH, Lee D, Koh SJ, Seo S, Lee GJ, Chun SH, Ji JH, Oh SY, Choi JW, Go SI. Oncologist. 2024 Nov 4;29(11):e1593-e1603.
11. Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study. Lee CK, Lee JB, Park SJ, Che J, Kwon WS, Kim HS, Jung M, Lee S, Park SR, Koo DH, Lee HW, Bae WK, Jeung HC, Hwang IG, Kim H, Nam CM, Chung HC, Rha SY. Gastric Cancer. 2024 Jan;27(1):118-130.
12. Effects of antipsychotic drugs during radiotherapy in breast cancer in South Korea: a retrospective cohort study. Hwang IG, Kim SM, Kang DR, Go TH, Hong SH, Park SY, Lee H, Choi JH. Sci Rep. 2024 Nov 7;14(1):27138.
13. Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06). Kim JW, Lee HJ, Lee JY, Park SR, Kim YJ, Hwang IG, Kyun Bae W, Byun JH, Kim JS, Kang EJ, Lee J, Shin SJ, Chang WJ, Kim EO, Sa JK, Park KH. J Immunother Cancer. 2024 Mar 13;12(3):e008638
14. SupporTive Care At Home Research (STAHR) for patients with advanced cancer: Protocol for a cluster non-randomized controlled trial. Lee DW, Lee SY, Yoo SH, Kim KH, Kim MS, Shin J, Hwang IY, Hwang IG, Baek SK, Kim DY, Kim YJ, Kang B, Lee J, Cho B. PLoS One. 2024 May 13;19(5):e0302011.
15. Practice guidelines for managing extrahepatic biliary tract cancers. Kim HS, Kang MJ, Kang J, Kim K, Kim B, Kim SH, Kim SJ, Kim YI, Kim JY, Kim JS, Kim H, Kim HJ, Nahm JH, Park WS, Park E, Park JK, Park JM, Song BJ, Shin YC, Ahn KS, Woo SM, Yu JI, Yoo C, Lee K, Lee DH, Lee MA, Lee SE, Lee IJ, Lee H, Im JH, Jang KT, Jang HY, Jun SY, Chon HJ, Jung MK, Chung YE, Chong JU, Cho E, Chie EK, Choi SB, Choi SY, Choi SJ, Choi JY, Choi HJ, Hong SM, Hong JH, Hong TH, Hwang SH, Hwang IG, Park JS. Ann Hepatobiliary Pancreat Surg. 2024 May 31;28(2):161-202.
16. Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study. Lee CK, Kim HS, Jung M, Kim H, Bae WK, Koo DH, Jeung HC, Park SR, Hwang IG, Zang DY, Lee HW, Park S, Nam CM, Chung HC, Rha SY. J Clin Oncol. 2024 Jan 20;42(3):348-357.
17. Diagnosis and outcomes of cachexia in Asia: Working Consensus Report from the Asian Working Group for Cachexia. Arai H, Maeda K, Wakabayashi H, Naito T, Konishi M, Assantachai P, Auyeung WT, Chalermsri C, Chen W, Chew J, Chou MY, Hsu CC, Hum A, Hwang IG, Kaido T, Kang L, Kamaruzzaman SB, Kim M, Lee JSW, Lee WJ, Liang CK, Lim WS, Lim JY, Lim YP, Lo RS, Ong T, Pan WH, Peng LN, Pramyothin P, Razalli NH, Saitoh M, Shahar S, Shi HP, Tung HH, Uezono Y, von Haehling S, Won CW, Woo J, Chen LK. J Cachexia Sarcopenia Muscle. 2023 Oct;14(5):1949-1958.
18. Feasibility and safety of exercise during chemotherapy in people with gastrointestinal cancers: a pilot study. Park SE, Kim DH, Kim DK, Ha JY, Jang JS, Choi JH, Hwang IG. Support Care Cancer. 2023 Sep 5;31(10):561.
19. Clinical Implication of DNA Damage Response Genes in Advanced Gastric Cancer Stage IV and Recurrent Gastric Cancer Patients After Gastrectomy Treated Palliative Chemotherapy. Kim JE, Park SE, Kim HJ, Hwang IG. J Cancer. 2023 May 5;14(7):1216-1222.
20. Real-world experience of safety and effectiveness of regorafenib for treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumors, and hepatocellular carcinoma: a post-marketing surveillance study in Korea. Beom SH, Bae KB, Zang DY, Bae J, Hwang IG, Kang HJ, Woo IS, Shim BY, Bae BN, Cheon J, Oh SB, Ahn JB. J Cancer. 2022 Sep 21;13(13):3396-3403.
21. COMPrehensive geriatric AsseSSment and multidisciplinary team intervent ion for hospitalised older adults (COMPASS): a protocol of pragmatic trials within a cohort. Choi JY, Lee JY, Shin J, Kim CO, Kim KJ, Hwang IG, Lee YG, Koh SJ, Hong S, Yoon SJ, Kang MG, Kim JW, Kim JH, Kim KI. BMJ Open. 2022 Aug 1;12(8)
22. Association between Timing and Duration of Adjuvant Chemotherapy and Colorectal Cancer Survival in Korea, 2011-2014: A Nationwide Study based on the Health Insurance Review and Assessment Service Database. Choi JH, Lee JS, Baek SK, Kim JG, Kim TW, Sohn SK, Kang MY, Lee SC, Hwang IG. J Cancer. 2022 May 1;13(8):2440-2446.
23. A phase II study of chemotherapy in combination with telomerase peptide vaccine (GV1001) as second-line treatment in patients with metastatic colorectal cancer. Kim S, Kim BJ, Kim I, Kim JH, Kim HK, Ryu H, Choi DR, Hwang IG, Song H, Kwon JH, Jung JY, Han B, Zang DY. J Cancer. 2022 Feb 14;13(4):1363-1369.
24. Low PARP-1 expression level is an indicator of poor prognosis in patients with stage II and III gastric cancer. Park SE, Kim HS, Jung EJ, Suh JH, Min H, Chi KC, Kim JW, Park JM, Hwang IG. J Cancer. 2022 Jan 1;13(3):869-876.
25. Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3). Go SI, Lee SC, Bae WK, Zang DY, Lee HW, Jang JS, Ji JH, Kim JH, Park S, Sym SJ, Yang Y, Jeon SY, Hwang IG, Oh SY, Kang JH. Eur J Cancer. 2021 Nov;157:21-30.
26. Clinical characteristics and survival of colorectal cancer patients in Korea stratified by age. Baek SK, Lee JS, Hwang IG, Kim JG, Kim TW, Sohn SK, Kang MY, Lee SC. Korean J Intern Med. 2021 Jul;36(4):985-991.
27. Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study. Hwang IG, Kwon M, Kim JW, Kim SH, Lee YG, Kim JY, Koh SJ, Ko YH, Shin SH, Hong S, Kim TY, Kim SY, Kim HJ, Kim HJ, Lee MA, Kwon JH, Hong YS, Lee KH, Bae SH, Koo DH, Kim JH, Woo IS. Cancers (Basel). 2021 Jan 18;13(2):331.
28. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12. Lee YG, Chang H, Keam B, Chun SH, Park J, Park KU, Shin SH, An HJ, Lee KE, Lee KW, Kim HR, Kim SB, Ahn MJ, Hwang IG. Cancer Res Treat. 2020 Dec 7. doi: 10.4143/crt.2020.824. Online ahead of print.
29. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. Park SH, Lim DH, Sohn TS, Lee J, Zang DY, Kim ST, Kang JH, Oh SY, Hwang IG, Ji JH, Shin DB, Yu JI, Kim KM, An JY, Choi MG, Lee JH, Kim S, Hong JY, Park JO, Park YS, Lim HY, Bae JM, Kang WK; ARTIST 2 investigators. Ann Oncol. 2020 Dec 3:S0923-7534(20)43172-2. doi: 10.1016/j.annonc.2020.11.017. Online ahead of print.
30. Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer. Park SE, Choi JH, Park JY, Kim BJ, Kim JG, Kim JW, Park JM, Chi KC, Hwang IG. Sci Rep. 2020 Oct 19;10(1):17683. doi: 10.1038/s41598-020-74765-8.
31. Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12. Park JH, Chun SH, Lee YG, Chang H, Lee KW, Kim HR, Shin SH, An HJ, Lee KE, Hwang IG, Ahn MJ, Kim SB, Keam B. J Cancer Res Clin Oncol. 2020 Dec;146(12):3359-3369.
32. Prognostic Value of CD200R1 mRNA Expression in Head and Neck Squamous Cell Carcinoma. Chang H, Lee YG, Ko YH, Cho JH, Choi JK, Park KU, Kang EJ, Lee KW, Lim SM, Kim JS, Lee HW, Kim MK, Hwang IG, Kim S, Nam BH, Kim HR. Cancers (Basel). 2020 Jul 3;12(7):1777. doi: 10.3390/cancers12071777.
33. Polypharmacy, Inappropriate Medication Use, and Drug Interactions in Older Korean Patients with Cancer Receiving First-Line Palliative Chemotherapy. Hong S, Lee JH, Chun EK, Kim KI, Kim JW, Kim SH, Lee YG, Hwang IG, Kim JY, Koh SJ, Ko YH, Shin SH, Woo IS, Kim TY, Baek JY, Kim HJ, Kim HJ, Lee MA, Kwon JH, Hong YS, Ryoo HM, Kim JH. Oncologist. 2020 Mar;25(3):e502-e511.
34. Incidence, Risk Factors, and Clinical Outcomes of Acute Kidney Injury Caused by Palliative Chemotherapy in Lung Cancer. Park SE, Hwang JH, Choi JH, Kim SH, Choi JC, Jang JS, Kim HJ, Park SW, Seok JW, Hwang IG. J Cancer. 2019 Aug 29;10(22):5332-5338. doi: 10.7150/jca.28399. eCollection 2019.
35. A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities. Kim YS, Ji JH, Oh SY, Lee S, Huh SJ, Lee JH, Song KH, Son CH, Roh MS, Lee GW, Lee J, Kim ST, Kim CK, Jang JS, Hwang IG, Ahn HK, Park LC, Oh SY, Kim SG, Lee SC, Lim DH, Lee SI, Kang JH. Oncologist. 2020 Jan;25(1):e186-e193.
36. Assessment of spatial tumor heterogeneity using CT growth patterns estimated by tumor tracking on 3D CT volumetry of multiple pulmonary metastatic nodules. Yoo J, Chong S, Lim C, Heo M, Hwang IG. PLoS One. 2019 Aug 1;14(8):e0220550.
37. The effects of BRCA1 expression on the chemosensitivity of gastric cancer cells to platinum agents. Kim G, Kim J, Han SY, Hwang IG, Kim HS, Min H. Oncol Lett. 2019 Jun;17(6):5023-5029.
38. Expression of DNA Damage Response Markers in Early-Onset or Familial Gastric Cancers Kim HS, Kim JW, Hwang IG, Lee HS, Kim WH. Asian Pac J Cancer Prev. 2019 May 25;20(5):1369-1376.
39. Clinical significance of BRCA1 and BRCA2 mRNA and protein expression in patients with sporadic gastric cancer. Kim HS, Hwang IG, Min HY, Bang YJ, Kim WH. Oncol Lett. 2019 May;17(5):4383-4392.
40. Serum biomarkers for predicting overall survival and early mortality in older patients with metastatic solid tumors. Kim SH, Kim JW, Hwang IG, Jang JS, Hong S, Kim TY, Baek JY, Shin SH, Sun S, Hong DS, Kim HJ, Hong YS, Woo IS, Lee JH, Kim JH. J Geriatr Oncol. 2019 Sep;10(5):749-756.
41. Sedation for terminally ill cancer patients: A multicenter retrospective cohort study in South Korea. Kim YS, Song HN, Ahn JS, Koh SJ, Ji JH, Hwang IG, Yun J, Kwon JH, Kang JH. Medicine (Baltimore). 2019 Feb;98(5):e14278.
42. Additional Chemotherapy with 5-FU plus Leucovorin between Preoperative Chemoradiotherapy and Surgery Improved Treatment Outcomes in Patients with Advanced Rectal Cancer. Park SE, Choi JH, Choi CH, Park SW, Kim BG, Cha SJ, Hwang IG. J Cancer. 2019 Jan 1;10(1):186-191.
43. Prospective Validation of The Korean Cancer Study Group Geriatric Score (KG)-7, a Novel Geriatric Screening Tool, in Older Patients with Advanced Cancer Undergoing First-line Palliative Chemotherapy. Kim JW, Kim SH, Lee YG, Hwang IG, Kim JY, Koh SJ, Ko YH, Shin SH, Woo IS, Hong S, Kim TY, Baek JY, Kim HJ, Kim HJ, Lee MA, Kwon JH, Hong YS, Ryoo HM, Lee KH, Kim JH. Cancer Res Treat. 2019 Jul;51(3):1249-1256.
44. A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST10-01). Lee KW, Maeng CH, Kim TY, Zang DY, Kim YH, Hwang IG, Oh SC, Chung JS, Song HS, Kim JW, Jeong SJ, Cho JY. Oncologist. 2019 Jan;24(1):18-e24.
45. Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma. Lim SM, Cho SH, Hwang IG, Choi JW, Chang H, Ahn MJ, Park KU, Kim JW, Ko YH, Ahn HK, Cho BC, Nam BH, Chun SH, Hong JH, Kwon JH, Choi JG, Kang EJ, Yun T, Lee KW, Kim JH, Kim JS, Lee HW, Kim MK, Jung D, Kim JE, Keam B, Yun HJ, Kim S, Kim HR. Cancer Res Treat. 2019 Jan;51(1):300-312.
46. The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study. Byun JH, Ahn JB, Kim SY, Kang JH, Zang DY, Kang SY, Kang MJ, Shim BY, Baek SK, Kim BS, Lee KH, Lee SI, Cho SH, Sohn BS, Kim S, Hwang IG, Nam EM, Seo BG, Oh SC, Lee MA, Lee SC, Hong JH, Park YS. Korean J Intern Med. 2019 Jan;34(1):165-177.
47. Sarcopenia is poor prognostic factor in older patients with locally advanced rectal cancer who received preoperative or postoperative chemoradiotherapy. Park SE, Hwang IG, Choi CH, Kang H, Kim BG, Park BK, Cha SJ, Jang JS, Choi JH. Medicine (Baltimore). 2018 Nov;97(48):e13363.
48. A case report of recurrent Merkel cell carcinoma with synchronous metastases to the heart and stomach. Ha JY, Park SE, Kim HS, Won H, Kim BJ, Hwang IG. Medicine (Baltimore). 2018 Nov;97(44):e13032.
49. A Randomized Phase 2 Trial of Consolidation Chemotherapy After Preoperative Chemoradiation Therapy Versus Chemoradiation Therapy Alone for Locally Advanced Rectal Cancer: KCSG CO 14-03. Kim SY, Joo J, Kim TW, Hong YS, Kim JE, Hwang IG, Kim BG, Lee KW, Kim JW, Oh HS, Ahn JB, Zang DY, Kim DY, Oh JH, Baek JY. Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):889-899.
50. Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study. Kim JH, Lee SC, Oh SY, Song SY, Lee N, Nam EM, Lee S, Hwang IG, Lee HR, Lee KT, Bae SB, Kim HJ, Jang JS, Lim DH, Lee HW, Kang SY, Kang JH. Cancer Commun (Lond). 2018 Jun 4;38(1):32.
51. Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean Cancer Study Group (KCSG) multicentre prospective study. Kim JW, Lee YG, Hwang IG, Song HS, Koh SJ, Ko YH, Shin SH, Woo IS, Hong S, Kim TY, Kim SY, Nam BH, Kim HJ, Kim HJ, Lee MA, Kwon JH, Hong YS, Bae SH, Koo DH, Kim KI, Kim JH. Br J Cancer. 2018 Mar 26. doi: 10.1038/s41416-018-0037-6. [Epub ahead of print]
52. Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). Jung M, Ryu MH, Oh DY, Kang M, Zang DY, Hwang IG, Lee KW, Kim KH, Shim BY, Song EK, Sym SJ, Han HS, Park YL, Kim JS, Lee HW, Lee MH, Koo DH, Song HS, Lee N, Yang SH, Choi DR, Hong YS, Lee KE, Maeng CH, Baek JH, Kim S, Kim YH, Rha SY, Cho JY, Kang YK. Gastric Cancer. 2018 Feb 9. doi: 10.1007/s10120-018-0806-1. [Epub ahead of print]
53. Practice Patterns in Distinguishing Between Background Pain and Breakthrough Pain During Patient Education: a Korean Physician Survey. Shin J, Kim DY, Lee J, Choi YS, Hwang IG, Baek SK, Seo MS, Shim JY. J Cancer Educ. 2018 Apr;33(2):284-292.
54. Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee. Kim MJ, Kim YS, Oh SY, Lee S, Choi YJ, Seol YM, Park MJ, Kim KH, Park LC, Kang JH, Hwang IG, Lee SI, Lim ST, Kim HS, Lim HY, Rha SY, Kim HJ. Korean J Intern Med. 2018 Mar;33(2):383-390.
55. The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study. Byun JH, Ahn JB, Kim SY, Kang JH, Zang DY, Kang SY, Kang MJ, Shim BY, Baek SK, Kim BS, Lee KH, Lee SI, Cho SH, Sohn BS, Kim S, Hwang IG, Nam EM, Seo BG, Oh SC, Lee MA, Lee SC, Hong JH, Park YS. Korean J Intern Med. 2017 Nov 28. doi: 10.3904/kjim.2016.348. [Epub ahead of print]
56. Chemotherapy Versus Best Supportive Care in Advanced Biliary Tract Carcinoma: A Multi-Institutional Propensity Score Matching Analysis. Ji JH, Kim YS, Park I, Lee SI, Kim RB, Park JO, Oh SY, Hwang IG, Jang JS, Song HN, Kang JH. Cancer Res Treat. 2017 Aug 23. doi: 10.4143/crt.2017.044. [Epub ahead of print]
57. Antiemetic Corticosteroid Rotation from Dexamethasone to Methylprednisolone to Prevent Dexamethasone-Induced Hiccup in Cancer Patients Treated with Chemotherapy: A Randomized, Single-Blind, Crossover Phase III Trial. Go SI, Koo DH, Kim ST, Song HN, Kim RB, Jang JS, Oh SY, Lee KH, Lee SI, Kim SG, Park LC, Lee SC, Park BB, Ji JH, Yi SY, Lee YG, Yun J, Bruera E, Hwang IG, Kang JH. Oncologist. 2017 Nov;22(11):1354-1361.
58. The Relationship between Physical Activity Intensity and Mental Health Status in Patients with Breast Cancer. Kang KD, Bae S, Kim HJ, Hwang IG, Kim SM, Han DH. J Korean Med Sci. 2017 Aug;32(8):1345-1350.
59. A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. Hwang IG, Ji JH, Kang JH, Lee HR, Lee HY, Chi KC, Park SW, Lee SJ, Kim ST, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK. J Geriatr Oncol. 2017 May;8(3):170-175.
60. The role of adjuvant therapy after R0 resection for patients with intrahepatic and perihilar cholangiocarcinomas. Kim YS, Oh SY, Go SI, Kang JH, Park I, Song HN, Ji JH, Hwang IG, Jang JS. Cancer Chemother Pharmacol. 2017 Jan;79(1):99-106.
61. Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma. Lim SH, Hwang IG, Ji JH, Oh SY, Yi JH, Lim DH, Lim HY, Lee SJ, Park SH. Asia Pac J Clin Oncol. 2017 Feb;13(1):61-67.
62. Choroidal and skin metastases from colorectal cancer. Ha JY, Oh EH, Jung MK, Park SE, Kim JT, Hwang IG. World J Gastroenterol. 2016 Nov 21;22(43):9650-9653.
63. Factors Influencing Clinicians' Choice of Adjuvant S-1 versus Capecitabine plus Oxaliplatin after Curative Gastrectomy in Patients with Gastric Cancer. Lee HY, Hwang IG, Park SE, Kim MJ, Park SH, Kang JH, Kim YS, Oh SY, Won YW, Lee SI, Ji JH, Chi KC. J Cancer. 2016 Jul 27;7(12):1711-1715.
64. Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma. Kim YS, Hwang IG, Park SE, Go SI, Kang JH, Park I, Oh SY, Ji JH, Song HN, Park SH, Kim ST, Park JO. Cancer Chemother Pharmacol. 2016 May;77(5):979-85. doi: 10.1007/s00280-016-3014-x.
65. Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects. Hwang IG, Kang JH, Oh SY, Lee S, Kim SH, Song KH, Son C, Park MJ, Kang MH, Kim HG, Lee J, Park YS, Sun JM, Kim HJ, Kim CK, Yi SY, Jang JS, Park K, Kim HJ. Support Care Cancer. 2016 Jan;24(1):301-9.
66. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma. Kim YS, Lee SI, Park SH, Park S, Hwang IG, Lee SC, Sun JM, Lee J, Lim HY. Clin Genitourin Cancer. 2016 Feb;14(1):76-81.
67. Is There a Role for Adjuvant Therapy in R0 Resected Gallbladder Cancer?: A Propensity Score-Matched Analysis. Go SI, Kim YS, Hwang IG, Kim EY, Oh SY, Ji JH, Song HN, Park SH, Park JO, Kang JH. Cancer Res Treat. 2016 Oct;48(4):1274-1285.
68. A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology. Yi JH, Kang JH, Hwang IG, Ahn HK, Baek HJ, Lee SI, Lim do H, Won YW, Ji JH, Kim HS, Rha SY, Oh SY, Lee KE, Lim T, Maeng CH, Kim MJ, Kim ST, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH. Cancer Res Treat. 2016 Apr;48(2):553-60. doi: 10.4143/crt.2015.155.
69. A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer. Lim SH, Kim TW, Hong YS, Han SW, Lee KH, Kang HJ, Hwang IG, Lee JY, Kim HS, Kim ST, Lee J, Park JO, Park SH, Park YS, Lim HY, Jung SH, Kang WK. Br J Cancer. 2015 Nov 17;113(10):1421-6.
70. Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06). Lee SJ, Kim TM, Kim YJ, Jang KT, Lee HJ, Lee SN, Ahn MS, Hwang IG, Lee S, Lee MH, Lee J. Oncologist. 2015 Nov;20(11):1312-9.
71. Long-Term Intermittent Palliative Sedation for Refractory Symptoms at the End of Life in Two Cancer Patients. Song HN, Lee US, Lee GW, Hwang IG, Kang JH, Eduardo B. J Palliat Med. 2015 Sep;18(9):807-10.
72. Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma. Lee MY, Jung KS, Kim HS, Lee JY, Lim SH, Kim M, Jung HA, Kim SM, Sun JM, Ahn MJ, Lee J, Park SH, Yi SY, Hwang IG, Lee SC, Ahn HK, Lim do H, Lee SI, Park KW. World J Gastroenterol. 2015 Apr 14;21(14):4268-74.
73. Retrospective analysis of extra-gastrointestinal stromal tumors. Yi JH, Park BB, Kang JH, Hwang IG, Shin DB, Sym SJ, Ahn HK, Lee SI, Lim do H, Park KW, Won YW, Lim SH, Park SH. World J Gastroenterol. 2015 Feb 14;21(6):1845-50.
74. Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer. Hwang IG, Jang JS, Oh SY, Rho MH, Lee S, Park YS, Park JO, Nam EM, Lee HR, Jun HJ, Chi KC. Cancer Chemother Pharmacol. 2015 Apr;75(4):757-62.
75. Natural history of metastatic biliary tract cancer (BTC) patients with good performance status (PS) who were treated with only best supportive care (BSC). Ji JH, Song HN, Kim RB, Oh SY, Lim HY, Park JO, Park SH, Kim MJ, Lee SI, Ryou SH, Hwang IG, Jang JS, Kim HJ, Choi JY, Kang JH. Jpn J Clin Oncol. 2015 Mar;45(3):256-60.
76. Occurrence of colonic liposarcoma after retroperitoneal liposarcoma. Choi JH, Hwang IG, Cha SJ, Lee TJ, Jang JS. Korean J Intern Med. 2015 Jan;30(1):125-8.
77. The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain. Kang JH, Oh SY, Song SY, Lee HY, Kim JH, Lee KE, Lee HR, Hwang IG, Park SH, Kim WS, Park YS, Park K. Korean J Intern Med. 2015 Jan;30(1):88-95
78. Treatment outcomes of gemcitabine alone versus gemcitabine plus platinum for advanced biliary tract cancer: a Korean Cancer Study Group retrospective analysis. Hwang IG, Song HS, Lee MA, Nam EM, Lim J, Lee KH, Lee KT, Zang DY, Jang JS. Cancer Chemother Pharmacol. 2014 Dec;74(6):1291-6.
79. Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study. Kim ST, Kang JH, Lee J, Park SH, Park JO, Park YS, Lim HY, Hwang IG, Lee SC, Park KW, Lee HR, Kang WK. Eur J Cancer. 2014 Nov;50(16):2822-30.
80. Chemotherapy in advanced gastric cancer patients associated with disseminated intravascular coagulation. Hwang IG, Choi JH, Park SH, Oh SY, Kwon HC, Lee SI, Lim do H, Lee GW, Kang JH. Cancer Res Treat. 2014 Jan;46(1):27-32.
81. The Clinical Impact of the Sum of the Maximum Standardized Uptake Value on the Pretreatment with F-FDG-PET/CT in Small-Cell Lung Cancer. Go SI, Song HN, Kang JH, Kang MH, Kim MJ, Jung J, Chung SI, Choi BH, Hwang IG, Kim SH, Ling H, Lee GW. Oncology. 2014;86(1):1-9.
82. Treatment of dexamethasone-induced hiccup in chemotherapy patients by methylprednisolone rotation. Lee GW, Oh SY, Kang MH, Kang JH, Park SH, Hwang IG, Yi SY, Choi YJ, Ji JH, Lee HY, Bruera E. Oncologist. 2013;18(11):1229-34.
83. Outcomes of third-line docetaxel-based chemotherapy in advanced gastric cancer who failed previous oxaliplatin-based and irinotecan-based chemotherapies. Lee MJ, Hwang IG, Jang JS, Choi JH, Park BB, Chang MH, Kim ST, Park SH, Kang MH, Kang JH. Cancer Res Treat. 2012 Dec;44(4):235-41.
84. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial. Sun JM, Lee KH, Kim SW, Lee DH, Min YJ, Yun HJ, Kim HK, Song HS, Kim YH, Kim BS, Hwang IG, Lee K, Jo SJ, Lee JW, Ahn JS, Park K, Ahn MJ; Korean Cancer Study Group. Cancer. 2012 Dec 15;118(24):6234-42.
85. A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer. Hwang IG, Jang JS, Oh SY, Lee S, Kwon HC, Lee GW, Go S, Kang MH, Cha YJ, Kang JH. Invest New Drugs. 2012 Dec;30(6):2371-6.
86. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. Kang JH, Lee SI, Lim do H, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH. J Clin Oncol. 2012 May 1;30(13):1513-8
87. Interstitial lung disease caused by TS-1: a case of long-term drug retention as a fatal adverse reaction. Park JM, Hwang IG, Suh SW, Chi KC. J Korean Surg Soc. 2011 Dec;81(6):414-8. Epub 2011 Nov 25.
88. Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL). Kim SJ, Choi CW, Mun YC, Oh SY, Kang HJ, Lee SI, Won JH, Kim MK, Kwon JH, Kim JS, Kwak JY, Kwon JM, Hwang IG, Kim HJ, Lee JH, Oh S, Park KW, Suh C, Kim WS. BMC Cancer. 2011 Jul 29;11:321.
89. Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients. Hwang IG, Jang JS, Do JH, Kang JH, Lee GW, Oh SY, Kwon HC, Jun HJ, Lim HY, Lee S, Chi KC, Lee SJ. Cancer Chemother Pharmacol. 2011 Oct;68(4):935-44. Epub 2011 Feb 5.
90. Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone. Kim SJ, Kang HJ, Kim JS, Oh SY, Choi CW, Lee SI, Won JH, Kim MK, Kwon JH, Mun YC, Kwak JY, Kwon JM, Hwang IG, Kim HJ, Park J, Oh S, Huh J, Ko YH, Suh C, Kim WS. Blood. 2011 Feb 10;117(6):1958-65. Epub 2010 Dec 9.
91. Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer. Lim do H, Park SH, Park KW, Kang JH, Oh SY, Hwang IG, Kwon JM, Lee SC, Lee HY, Kim HS, Lim HY, Kang WK. BMC Cancer. 2010 Oct 26;10:583.
92. Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study. Oh SY, Kim WS, Kim JS, Kim SJ, Lee S, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Chae YS, Yang DH, Kang HJ, Choi CW, Park J, Kim HJ, Kwon JH, Lee HS, Lee GW, Eom HS, Kwak JY, Lee WS, Suh C, Kim HJ. Int J Hematol. 2010 Oct;92(3):510-7. Epub 2010 Sep 14.
93. Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study. Oh SY, Kim WS, Kim JS, Kim SJ, Lee S, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Chae YS, Yang DH, Kang HJ, Choi CW, Park J, Kim HJ, Kwon JH, Lee HS, Lee GW, Eom HS, Kwak JY, Suh C, Kim HJ. Cancer Sci. 2010 Nov;101(11):2443-7. doi: 10.1111/j.1349-7006.2010.01698.x.
94. Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. Oh SY, Jeong CY, Hong SC, Kim TH, Ha CY, Kim HJ, Lee GW, Hwang IG, Jang JS, Kwon HC, Kang JH. Invest New Drugs. 2011 Oct;29(5):1066-72. Epub 2010 Apr 1.
95. Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study. Oh SY, Kim WS, Kim JS, Kim SJ, Kwon HC, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Chae YS, Yang DH, Lee GW, Choi CW, Park J, Suh C, Kim HJ. Ann Hematol. 2010 Jun;89(6):563-8. Epub 2009 Dec 19.
96. Relapsed or refractory nongastric marginal zone B-cell lymphoma: multicenter retrospective analysis of 92 cases. Oh SY, Kim WS, Kim SJ, Kim JS, Kim SH, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Kim JG, Yang DH, Kang HJ, Choi CW, Park J, Choi YJ, Kim HJ, Kwon JH, Suh C, Kim HJ. Am J Hematol. 2009 Dec;84(12):826-9.
97. Gastric leptomeningeal carcinomatosis: multi-center retrospective analysis of 54 cases. Oh SY, Lee SJ, Lee J, Lee S, Kim SH, Kwon HC, Lee GW, Kang JH, Hwang IG, Jang JS, Lim HY, Park YS, Kang WK, Kim HJ. World J Gastroenterol. 2009 Oct 28;15(40):5086-90.
98. Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial. Jang JS, Lim HY, Hwang IG, Song HS, Yoo N, Yoon S, Kim YH, Park E, Byun JH, Lee MA, Oh SJ, Lee KH, Kim BS, Oh SC, Kim SY, Lee SJ. Cancer Chemother Pharmacol. 2010 Mar;65(4):641-7. Epub 2009 Aug 4.
99. L1 cell adhesion molecule as a predictor for recurrence in pulmonary carcinoids and large-cell neuroendocrine tumors. Kim HS, Yi SY, Jun HJ, Ahn JS, Ahn MJ, Lee J, Kim Y, Cui ZY, Hong HJ, Kim JM, Li S, Hwang IG, Park K. APMIS. 2009 Feb;117(2):140-6.
100. Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer. Chang MH, Kim KH, Jun HJ, Kim HS, Yi SY, Uhm JE, Park MJ, Lim do H, Ji SH, Hwang IG, Lee J, Park YH, Ahn JS, Ahn MJ, Park K. Cancer Chemother Pharmacol. 2009 Oct;64(5):917-24. Epub 2009 Feb 17.
101. Molecular biomarkers for advanced renal cell carcinoma: implications for prognosis and therapy. Hwang IG, Kim HS, Kim WS, Park SH, Jung CW, Choi HY, Lee HM, Jeon SS, Ha H, Lee S, Lim HY. Urol Oncol. 2010 Mar-Apr;28(2):157-63. Epub 2008 Oct 31.
102. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Hwang IG, Ahn MJ, Park BB, Ahn YC, Han J, Lee S, Kim J, Shim YM, Ahn JS, Park K. Cancer. 2008 Sep 15;113(6):1379-86.
103. Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma. Park BB, Im YH, Hwang IG, Lee SC, Ahn JS, Ahn MJ, Lim HY, Kang WK, Park K. Invest New Drugs. 2008 Aug;26(4):387-92. Epub 2008 Mar 27.
104. Combination chemotherapy with irinotecan and cisplatin in elderly patients (>or= 65 years) with extensive-disease small-cell lung cancer. Kim HG, Lee GW, Kang JH, Kang MH, Hwang IG, Kim SH, Hahm JR, Jeong YY, Kim HC, Lee JD, Lee JS, Hwang YS. Lung Cancer. 2008 Aug;61(2):220-6. Epub 2008 Feb 12.
105. Clinicopathologic features and treatment outcomes in malignant lymphoma of pediatric and young adult patients in Korea: comparison of korean all-ages group and Western younger age group. Hwang IG, Yoo KH, Lee SH, Park YH, Lim TK, Lee SC, Park S, Park BB, Ko YH, Kim K, Koo HH, Kim WS. Clin Lymphoma Myeloma. 2007 Nov;7(9):580-6.
106. Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease. Oh SY, Kwon HC, Kim WS, Hwang IG, Park YH, Kim K, Ko YH, Ryoo BY, Kang HJ, Nam E, Lee JH, Kim JH, Kim HJ. Eur J Haematol. 2007 Oct;79(4):287-91. Epub 2007 Aug 10.
107. Combination chemotherapy with paclitaxel and ifosfamide as the third-line regimen in patients with heavily pretreated small cell lung cancer. Park S, Ahn MJ, Ahn JS, Lee J, Hong YS, Park BB, Lee SC, Hwang IG, Park JO, Lim H, Kang WK, Park K. Lung Cancer. 2007 Oct;58(1):116-22. Epub 2007 Jul 12.
108. The impact of Epstein-Ba rr virus status on clinical outcome in diffuse large B-cell lymphoma. Park S, Lee J, Ko YH, Han A, Jun HJ, Lee SC, Hwang IG, Park YH, Ahn JS, Jung CW, Kim K, Ahn YC, Kang WK, Park K, Kim WS. Blood. 2007 Aug 1;110(3):972-8. Epub 2007 Mar 30.
109. Changes in serologic markers of hepatitis B following autologous hematopoietic stem cell transplantation. Uhm JE, Kim K, Lim TK, Park BB, Park S, Hong YS, Lee SC, Hwang IG, Koh KC, Lee MH, Ahn JS, Kim WS, Jung CW, Kang WK. Biol Blood Marrow Transplant. 2007 Apr;13(4):463-8.
110. Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome. Han AR, Lee HR, Park BB, Hwang IG, Park S, Lee SC, Kim K, Lim HY, Ko YH, Kim SH, Kim WS. Ann Hematol. 2007 Jul;86(7):493-8. Epub 2007 Mar 9.
111. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. Hong YS, Lee J, Lee SC, Hwang IG, Choi SH, Heo JS, Park JO, Park YS, Lim HY, Kang WK. Cancer Chemother Pharmacol. 2007 Aug;60(3):321-8. Epub 2006 Dec 2.
112. Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer. Hong YS, Lee HR, Park S, Lee SC, Hwang IG, Park BB, Lee J, Ahn JS, Ahn MJ, Lim HY, Park K. Br J Cancer. 2006 Dec 18;95(12):1648-52. Epub 2006 Nov 28.